STEMdiff™三细胞分化试剂盒

通过人类胚胎干细胞和iPS细胞定向分化到所有三个胚层来评估多能性的功能测定试剂盒

产品号 #(选择产品)

产品号 #05230_C

通过人类胚胎干细胞和iPS细胞定向分化到所有三个胚层来评估多能性的功能测定试剂盒

产品优势

  • 在多个多能细胞系中向所有三个胚层可重复分化
  • 易于解释的分析结果
  • 完整的、明确的培养基
  • 标准化的,为期一周的协议

产品组分包括

  • STEMdiff™三龄外胚层培养基,175 mL
  • STEMdiff™三叶中胚层培养基,100 mL
  • STEMdiff™三层内胚层培养基,100 mL
Products for Your Protocol
To see all required products for your protocol, please consult the Protocols and Documentation.

概述

STEMdiff™三龄分化试剂盒提供简单的培养试验,从功能上验证新的或已建立的人胚胎干(ES)和诱导多能干(iPS)细胞系分化为三个胚层的能力:外胚层、中胚层和内胚层。该试剂盒包括专门的、完整的培养基和基于单层的方案,用于对每个胚层进行平行的体外定向分化实验,在一周内清晰、可重复地建立三龄分化潜力。STEMdiff™Trilineage分化试剂盒旨在作为终点检测,未针对下游分化或其他应用的细胞生成进行优化。STEMdiff™三期分化试剂盒已经过优化,可用于评估mTeSR™1、mTeSR™Plus或TeSR™- AOF中维持的细胞。

Subtype
Specialized Media
 
Cell Type
Pluripotent Stem Cells
 
Species
Human
 
Application
Cell Culture, Characterization, Differentiation, Functional Assay, Phenotyping
 
Brand
STEMdiff
 
Area of Interest
Stem Cell Biology
 

Protocols and Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Catalog #
05230
Lot #
All
Language
English
Document Type
Safety Data Sheet 1
Catalog #
05230
Lot #
All
Language
English
Document Type
Safety Data Sheet 2
Catalog #
05230
Lot #
All
Language
English
Document Type
Safety Data Sheet 3
Catalog #
05230
Lot #
All
Language
English

Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Resources and Publications

Educational Materials (32)

Publications (3)

Feeder-Free Derivation of Naïve Human Pluripotent Stem Cells. Ward E et al. Stem cells and development 2017 MAY

Abstract

Human pluripotent stem cells (HPSCs) cultured in conditions that maintain pluripotency via FGF and TGFβ signaling have been described as being in a primed state. These cells have been shown to exhibit characteristics more closely related to mouse epiblast-derived stem cells than to so called naïve mouse PSCs said to possess a more ground state pluripotency that mimics the early mouse embryo inner cell mass. Initial attempts to create culture conditions favorable for generation of naïve HPSCs from primed HPSCs has required the use of mouse embryonic fibroblasts as a feeder layer to support this transition. A protocol for the routine derivation and maintenance of naïve HPSCs in completely defined conditions is highly desirable for stem cell researchers to enhance the study and clinical translation of naïve HPSCs. Here we describe a standard protocol for transitioning primed HPSCs to a naïve state using commercial RSet media and xeno-free recombinant vitronectin.
Peripheral blood derived induced pluripotent stem cells (iPSCs) from a female with familial hypertrophic cardiomyopathy. S. B. Ross et al. Stem cell research 2017

Abstract

Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) obtained from a 62-year-old female with familial hypertrophic cardiomyopathy (HCM). PBMCs were reprogrammed to a pluripotent state following transfection with non-integrative episomal vectors carrying reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotency markers, possess trilineage differentiation potential, carry rare variants identified in DNA isolated directly from the patient's whole blood, have a normal karyotype and no longer carry episomal vectors for reprogramming. This line is a useful resource for identifying unknown genetic causes of HCM.
Generation of induced pluripotent stem cells (iPSCs) from a hypertrophic cardiomyopathy patient with the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7) gene. S. B. Ross et al. Stem cell research 2017

Abstract

Induced pluripotent stem cells (iPSCs) were generated from peripheral blood mononuclear cells (PBMCs) isolated from the whole blood of a 43-year-old male with hypertrophic cardiomyopathy (HCM) who carries the pathogenic variant p.Val698Ala in beta-myosin heavy chain (MYH7). Patient-derived PBMCs were reprogrammed using non-integrative episomal vectors containing reprogramming factors OCT4, SOX2, LIN28, KLF4 and L-MYC. iPSCs were shown to express pluripotent markers, have trilineage differentiation potential, carry the pathogenic MYH7 variant p.Val698Ala, have a normal karyotype and no longer carry the episomal reprogramming vector. This line is useful for studying the link between variants in MYH7 and the pathogenesis of HCM.

更多信息

更多信息
Species Human
For related products, including specialized media, matrices, antibodies, cytokines, and small molecules, visit www.stemcell.com/hPSCworkflow, or contact us at techsupport@stemcell.com.
版权 © 2025 STEMCELL Technologies 技术有限公司。保留所有权利。